about
MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1RPsoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort studyCommunity differentiation of the cutaneous microbiota in psoriasisTonsillectomy as a treatment for psoriasis: a reviewNew developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastOral fumaric acid esters for psoriasisIndoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasisOral fumaric acid esters for psoriasisZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiationUstekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primerPromising new treatments for psoriasisNicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in miceDefinition of treatment goals for moderate to severe psoriasis: a European consensusEmerging therapies for the treatment of psoriasisT helper 17 cell heterogeneity and pathogenicity in autoimmune diseaseCytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesionsAssociation analyses identify six new psoriasis susceptibility loci in the Chinese populationApremilast in the therapy of moderate-to-severe chronic plaque psoriasisImmune Signatures in Patients with Psoriasis Vulgaris of Blood-Heat Syndrome: A Systematic Review and Meta-AnalysisRecent advances in understanding psoriasisNail Psoriasis: A Review of Treatment OptionsA Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque PsoriasisAssociation between Psoriasis and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysisFunctional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell ResponsesExploring the Physiological Link between Psoriasis and Mood DisordersBiomarkers of An Autoimmune Skin Disease--PsoriasisAtherosclerosis in psoriatic disease: latest evidence and clinical implicationsIndirubin and Indirubin Derivatives for Counteracting Proliferative DiseasesHLA-B27 and psoriatic disease: a modern view of an old relationshipRole of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and CancerThe role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritisJanus kinase inhibitors in autoimmune diseasesImmunology of psoriasisNew era of biologic therapeutics in atopic dermatitisJakpot! New small molecules in autoimmune and inflammatory diseasesThe new insight into the role of antimicrobial proteins-alarmins in the immunopathogenesis of psoriasisInnate lymphoid cells in the skinRelationships between Adipose Tissue and Psoriasis, with or without ArthritisTargeting of interleukin-17 in the treatment of psoriasisAge at disease onset: a key factor for understanding psoriatic disease
P2860
Q21135346-E88EF45F-29D4-410E-9062-486D32DFB7EDQ21135505-50CB6B95-AB0C-4139-8BA0-92B2E8D9B2D0Q21195810-BF84C59E-32EA-4209-9016-0B164C11E75DQ22305701-888797C8-A51F-49D0-A836-40A48514D536Q22305855-10F61D46-AB51-462A-84BD-E03FCC77D4A6Q24187957-518322D0-91D3-4BCD-B213-E9F8E9225F6CQ24188256-5E565C82-CD66-4E68-9502-FAD85F9FACE4Q24198185-609E06F9-CA3B-471C-A171-CA570821F92CQ24306117-CBBABAF7-7159-4DED-8F8A-BDA3921A26B0Q24596756-97A14C58-CFC6-4255-A9AC-3BA14B93F54AQ24598008-9ABE659C-941A-42DE-9D84-A67116E888A2Q24600864-CF0245AF-53FD-46E2-AE89-B7697D890549Q24604445-32E4CAF5-0B0C-4C82-8876-77079143C205Q24605738-C9A6B8EF-DB2E-4486-ABA8-BF6FE872C555Q24609737-88E0E060-F3C5-4F91-B1A8-084B4C18E36EQ24629755-272165F6-99C3-47AD-A3DF-3BE66B7EEC15Q24630768-32C63F3F-494F-40B1-970F-D2109275C3EDQ26745789-B5A39ECF-6264-4FC5-B16E-A0D29B16F2CFQ26747616-2D568BE4-5847-4859-BF5D-EF7C2419401FQ26751223-1872397E-995F-4133-97D3-81A7A604DF36Q26753038-C9A4D91C-87EC-4878-BEFD-7A5B41D3D7EAQ26771682-C271B715-C065-47B1-B30B-A0A93C95F988Q26772143-155CD803-9356-4968-A5EB-F03A6C94F0D5Q26777948-6F8E8D9F-0F80-4A8B-9F86-9AABB640E2F3Q26778531-D823ADD4-033B-42A9-B349-F8D3343C74ADQ26781378-44E47B1B-195E-4BB0-A606-90F684B68DCFQ26783501-8FAB5FE8-CDAE-4F06-B01E-3CE32F3BA9F0Q26784341-53263360-9FD7-4401-A704-EBF617389038Q26796433-2BEE0AA5-D4BC-4281-8020-CBA4D550F827Q26800202-8EE64896-70E1-4736-86BB-F3A377A9EF6CQ26821943-13BB019F-F85D-4671-9000-34FC0D1DD69BQ26865446-B30142B2-431F-4CC2-8A8D-D34897E0FEDAQ26995800-BA0B3287-D186-4430-B297-DEC15DCB9C2AQ27001941-25B17854-9E7F-4E6F-930E-9CD4F4D35F20Q27001957-F38D1553-7E3B-4BB8-B1D4-98F3EF27E3E8Q27007680-C522EB54-25D4-4E98-8D2D-E82EBD210BF0Q27023221-0C25D672-AB50-4E10-A819-E4B34F9F8C95Q27025534-3DC758EA-228F-4182-82E2-D3AA3FB90882Q27026324-D1494F4C-16E8-4658-B513-D0FD34ADBB1BQ27026745-37B8A780-F34E-490B-A8EA-DFCA24E8A0B0
P2860
description
im Juli 2009 veröffentlichter wissenschaftlicher Artikel
@de
наукова стаття, опублікована в липні 2009
@uk
name
Psoriasis
@en
type
label
Psoriasis
@en
prefLabel
Psoriasis
@en
P356
P1476
Psoriasis
@en
P2093
Daniel H. Kaplan
Frank O. Nestle
P304
P356
10.1056/NEJMRA0804595
P407
P577
2009-07-30T00:00:00Z